



2024/1/22

產業類別	生技	
投資建議	買進	
收盤價	NT\$ 288.50	目標價
		NT\$ 375.00

本次報告：公司拜訪

交易資料

潛在報酬率 (%)	29.98
52 週還原收盤價區間 (NT\$)	208.50-339.50
市值 (NT\$百萬元)	76450
市值 (US\$百萬元)	2,432
流通在外股數 (百萬股)	265.00
董監持股 (%)	41.12
外資持股 (%)	65.82
投信持股 (%)	5.61
融資使用率 (%)	24.43

財務資料

	2022
股東權益 (NT\$百萬元)	13,868
ROA (%)	11.9
ROE (%)	24.23
淨負債比率 (%)	53.03

公司簡介

美時為一從事困難學名藥與癌症學名藥之製造及銷售藥廠，近年持續透過自行開發、授權合作、收購等方式壯大營運規模，3Q23 以科別分類，腫瘤、中樞神經、基礎醫護與生活品質、女性健康及腎臟科營收占比各為 38%、30%、24%、4%及 4%，銷售區域部分，全球外銷市場營收比各為：亞太地區 51%、美國 43%、其他 6%。

陳奕均 fion.chen@sinopac.com

美時 (1795 TT)

多元產品及市場布局持續發酵


永豐觀點

多元產品及市場布局策略奏效，美時中長期獲利持續揚升。

投資評價與建議


投資建議買進：由於(1)2024 年美國市場兩大主力藥品，血癌藥營收將再有感增長，戒毒癮藥在需求量增下，營收表現預期將持穩；(2)其餘市場部分，南韓市場持續布局體重管理與老年相關領域藥品，台灣品牌藥帶動學名藥銷售及渠道再擴充策略奏效，東南亞積極透過引進品牌藥及併購事業加速成長下，整體展望正向；(3)繼血癌藥至 2025 年底確定可為美時帶來豐厚獲利貢獻外，市場規模也不小之在研藥品 Pomalidomide(全球市場銷值約 9 億美金)、Midostaurin(全球市場銷值約 5.1 億美金)、Nintedanib(全球市場銷值約 35 億美金)及 Tofacitinib(全球市場銷值約 3.8 億美金)等可望於 2025~2026 年在主力市場陸續接棒上市下，美時中長期獲利將持續揚升，維持買進，目標價 375 元(17 X 2024 EPS)。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Jan. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Jan. 2024

營運現況與分析

公司簡介：美時為一從事困難學名藥與癌症學名藥之製造及銷售藥廠，近年持續透過自行開發、授權合作、收購等方式壯大營運規模，3Q23 以科別分類，腫瘤、中樞神經、基礎醫護與生活品質、女性健康及腎臟科營收占比各為 38%、30%、24%、4%及 4%，銷售區域部分，亞太地區及全球外銷市場營收比各為 51%，亞太區中，韓國、台灣及其他亞洲各佔 34%、13%及 4%，全球外銷市場美國佔 43%，其他 6%。

4Q23 營收表現符合預期，預估 2023 年稅後 EPS 15 元：美時 4Q 營收 34.2 億元 (-25.2%QoQ、+7.8%YoY)，表現符合預期，總計 2023 年營收 169.6 億元 (+15.9%YoY)，其中，亞洲市場在台灣及東南亞地區品牌藥併購效益帶動下，營收 YoY 達 22%，外銷市場也在血癌藥及戒毒癮藥兩大主力產品業績成長下，營收 YoY 為 10%，總計預估毛利率 56.1%，稅後淨利 39.8 億元(+31.6%YoY)，稅後 EPS 15 元。

多元產品及市場布局加乘效果持續顯現：

- (1) 美國市場：營收占比約 40-45%，為公司最大營收貢獻來源，藥品銷售品項以血癌藥 Lena 及戒毒癮藥 Buprenorphin/Naloxone 為主，在血癌藥部分，由於與原廠協議中，至 2025 年底出貨量將有條件逐年放大，加上因已上市之學名藥廠佔整體市佔率低，故並未出現價格競爭狀下，預計 2024 年將可為美時帶來 60 億元以上營收貢獻，出貨排程上，考量供應鏈調配，今年將採更平穩方式鋪貨，預計約 2~3 個月出貨一次，即今年 1Q 可能會平均於 1 及 3 月進行出貨，且整體出貨期將延長至 4Q，另戒毒癮藥部分，終端需求持續增長，且因此藥生產製程複雜，新競爭者再進入應有限下，預估 2024 年戒毒癮藥營收表現將可持穩。
- (2) 韓國市場：營收占比約 30-35%，美時韓國市場除減肥藥品 Qsymia 銷售穩定外，公司也積極布局體重管理衍生領域如血糖控制、心血管等及骨質酥鬆、帕金森氏症等老年相關藥品市場下，預期韓國市場營收將維持 5-10%成長表現，而在生物相似藥上，與大昌華嘉子公司 Favorex 合作引進之自體免疫疾病藥品 Ustekinumab 及與 Intas 合作引進治療骨質酥鬆暨癌症藥品 Denosumab 皆在進行進入市場相關程序之申請，並預計 1-2 年後上市銷售。
- (3) 台灣市場：營收占比約 10-15%，美時近兩年在陸續併入 Alyssa、Alima、Cialis 等品牌藥策略奏效，成功帶動其餘學名藥銷售及打入診所渠道下，營收成長動能強勁，未來將延續此策略持續強化銷售動能。
- (4) 東南亞市場：營收占比 <5%，看好東南亞市場發展潛力，美時聚焦之科別為癌症與健康相關，營運上，將複製台灣模式包括引進品牌藥甚或進行事業併購，加速公司在東南亞市場成長動能。

財務預估：預估美時 2024 年營收 205.6 億元(+21.3%YoY)，毛利率 60.1%，稅後淨利 58.5 億元(+47.2%YoY)，稅後 EPS 22.08 元。

附表一：當年度損益表

單位：百萬元	24Q1F	24Q2F	24Q3F	24Q4F	2024F
營業收入	5,430	5,710	5,810	3,612	20,563
營業毛利	3,448	3,597	3,695	1,626	12,367
營業利益	2,368	2,497	2,565	445	7,875
稅前淨利	2,251	2,380	2,448	328	7,407
稅後純益	1,778	1,880	1,934	259	5,851
稅後 EPS (元)	6.71	7.09	7.3	0.98	22.08
營收 QoQ 成長率	58.82	5.16	1.75	-37.83	--
營收 YoY 成長率	20.05	28.57	27.05	5.64	21.26
毛利率	63.50	62.99	63.60	45.02	60.14
營益率	43.61	43.73	44.15	12.32	38.30
稅後純益率	32.74	32.92	33.29	7.17	28.45

資料來源：CMoney；永豐投顧研究處整理 · Jan. 2024

附表二：五個年度損益表

單位：百萬元	2020	2021	2022	2023F	2024F
營業收入	10,729	12,649	14,633	16,958	20,563
%變動率	11.63	17.90	15.68	15.89	21.26
營業毛利	4,597	5,640	7,806	9,510	12,367
毛利率 (%)	42.84	44.59	53.35	56.08	60.14
營業淨利	1,613	2,295	4,111	5,218	7,875
稅前淨利	1,304	1,870	3,940	4,936	7,407
%變動率	33.49	43.38	110.70	25.28	50.06
稅後純益	1,027	1,403	3,021	3,975	5,851
%變動率	54.92	36.67	115.25	31.58	47.19
稅後 EPS * (元)	4.22	5.50	11.59	15	22.08
市調 EPS * (元)	3.85	5.95	11.49	15.62	18.97
PER (x)	68.36	52.45	24.89	19.23	13.07
PBR (x)	8.09	6.85	5.46	4.74	3.75
每股淨值 * (元)	35.64	42.12	52.81	60.92	77
每股股利 (元)	0.35	1.93	3.46	--	--
殖利率 (%)	0.45	2.03	1.42	--	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理 · Jan. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2022	2023	2022	2023	2022	2023


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨週轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
----	---	---

香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288
----	---

上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220
----	---

倫敦	永豐金證券(歐洲)有限公司 6 Lloyds Avenue, London EC3N 3AX, UK 電話：(44-20) 7614-9999
----	---

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤
N：Neutral 中立：未來 12 個月該股票表現將與大盤一致
S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Notice for UK Persons**

This Document may only be issued or passed on to any person in the United Kingdom if that person is of a kind described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2001 or otherwise pursuant to exemptions to section 21 of the Financial Services and Markets Act 2000. In addition, no person who is an Authorized Person may issue or pass on this document, or otherwise promote SPSE, to any person in the United Kingdom other than by the rules of the Financial Conduct Authority (FCA) applicable to such Authorized Persons. This Document is confidential and is intended solely for the use of its recipient.

Important Disclosures for U.S. Persons

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.

SinoPac Securities (Europe) Limited is regulated by the FCA